SEC 13F Intelligence

Mpm Bioimpact LLC / TVTX

Mpm Bioimpact LLC’s Travere Therapeutics Inc Position

Does Mpm Bioimpact LLC own Travere Therapeutics Inc (TVTX)? Yes — 1.13M shares worth $34M (+2.60% of its 13F portfolio) as of Q1 2026, up from 552.8K shares the prior filed quarter.

Position Value
$34M
Q1 2026
Shares
1.13M
% of Portfolio
+2.60%
Quarters Held
10
currently held

Position History TVTX

Reported value by quarter
Q3 ’21: $7MQ3 ’21Q4 ’21: $9MQ1 ’22: $7MQ1 ’22Q2 ’22: $7MQ3 ’22: $7MQ3 ’22Q4 ’22: $6MQ1 ’23: $7MQ1 ’23Q2 ’23: $8MQ3 ’23: $5MQ3 ’23Q1 ’26: $34Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 20261.13M$34M+2.60%
Q3 2023552.8K$5M+1.32%
Q2 2023552.8K$8M+1.71%
Q1 2023313.6K$7M+1.83%
Q4 2022281.7K$6M+1.54%
Q3 2022276.5K$7M+1.61%
Q2 2022277.9K$7M+1.87%
Q1 2022277.9K$7M+1.92%
Q4 2021287.9K$9M+1.63%
Q3 2021306.5K$7M+1.15%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Mpm Bioimpact LLC’s full portfolio or all institutional holders of TVTX.